Company / Current Liabilities
Outlook Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$45.8M
FY2025
5-year range
$15.9M / $45.8M
FY2021-FY2025
Trend
+188.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $46M.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +23.6%.
Increased from $20M to $46M over the past 6 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +23.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +23.6%, indicating consistent growth.
- In FY2025, current liabilities increased 188.3% year-over-year.
- Lowest current liabilities in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.8M | +188.3% |
| FY2020 | $15.9M | -21.7% |
| FY2019 | $20.3M | -36.7% |
| FY2018 | $32.0M | +11.5% |
| FY2017 | $28.7M | +40.6% |
| FY2016 | $20.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026